LONDON and PHILADELPHIA – June 23, 2026 – Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announces that all resolutions were duly passed by shareholders at the Annual General Meeting (AGM), which was held on Monday June 22.
The results of the voting at the AGM are outlined in the table below and the presentation materials are available on the Company’s website here.
